CMMB · Chemomab Therapeutics Ltd. · Executive Compensation
Market Cap
$11.72M
Shares
7.33M
Volume · Oct 6
11.95K
Avg daily vol (3M)
160.33K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Nissim Darvish | Chairman of the Board | Appointed | 2023-06-05 |
| Ms. Sigal Fattal | Chief Financial Officer | Appointed | 2023-06-05 |
| Dr. Adi Mor | Chief Executive Officer | Appointed | 2023-06-05 |
| Matthew B. Frankel | Chief Medical Officer & VP, Drug Development | Appointed | 2022-11-14 |